Fabrication of Curcumin Diethyl γ-Aminobutyrate-Loaded Chitosan-Coated Magnetic Nanocarriers for Improvement of Cytotoxicity against Breast Cancer Cells.
Box–Behnken design
cytotoxicity
iron oxide nanoparticles
magnetic targeting delivery
prodrug
Journal
Polymers
ISSN: 2073-4360
Titre abrégé: Polymers (Basel)
Pays: Switzerland
ID NLM: 101545357
Informations de publication
Date de publication:
19 Dec 2022
19 Dec 2022
Historique:
received:
16
11
2022
revised:
15
12
2022
accepted:
15
12
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
24
12
2022
Statut:
epublish
Résumé
This study shows the effectiveness of magnetic-guide targeting in the delivery of curcumin diethyl γ-aminobutyrate (CUR-2GE), a prodrug of curcumin (CUR) previously synthesized to overcome unfavorable physicochemical properties of CUR. In this study, chitosan (Ch)-coated iron oxide nanoparticles (Ch-IONPs) were fabricated and optimized using Box-Behnken design-based response surface methodology for delivery of CUR-2GE. Ch was used as a coating material on the nanoparticle surface to avoid aggregation. The optimized condition for preparing Ch-IONPs consisted of using 4 mg Ch fabricated at pH 11 under a reaction temperature of 85 °C. The optimized Ch-IONPs were successfully loaded with CUR-2GE with sufficient loading capacity (1.72 ± 0.01%) and encapsulation efficiency (94.9 ± 0.8%). The obtained CUR-2GE-loaded Ch-IONPs (CUR-2GE-Ch-IONPs) exhibited desirable characteristics including a particle size of less than 50 nm based on TEM images, superparamagnetic property, highly crystalline IONP core, sufficient stability, and sustained-release profile. In the presence of permanent magnets, CUR-2GE-Ch-IONPs significantly increased cellular uptake and cytotoxicity toward MDA-MB-231 with a 12-fold increase in potency compared to free CUR-2GE, indicating the potential of magnetic-field assisted delivery of CUR-2GE-Ch-IONPs for the treatment of triple-negative breast cancer.
Identifiants
pubmed: 36559930
pii: polym14245563
doi: 10.3390/polym14245563
pmc: PMC9785553
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Thailand Science Research and Innovation Fund Chulalongkorn University
ID : HEA666200114
Organisme : the Ratchadaphiseksomphot Endowment Fund, Chulalongkorn University on the Center of Ex-cellence in Natural Products for Ageing and Chronic Diseases, Chulalongkorn University
ID : GCE 6503433003-1
Organisme : The 90th Anniversary Chulalongkorn University Fund under the Ratchadaphiseksomphot En-dowment Fund of the Graduate School, Chulalongkorn University
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Angew Chem Int Ed Engl. 2007;46(8):1222-44
pubmed: 17278160
Adv Drug Deliv Rev. 2011 Jan-Feb;63(1-2):24-46
pubmed: 20685224
Nanomaterials (Basel). 2020 Sep 25;10(10):
pubmed: 32992815
Front Microbiol. 2018 Jul 24;9:1639
pubmed: 30087662
Adv Exp Med Biol. 2007;595:105-25
pubmed: 17569207
Pharmaceutics. 2019 Nov 12;11(11):
pubmed: 31726769
ACS Nano. 2013 May 28;7(5):3939-52
pubmed: 23634880
Sci Rep. 2018 Oct 18;8(1):15397
pubmed: 30337616
Colloids Surf B Biointerfaces. 2019 Apr 1;176:462-470
pubmed: 30682619
3 Biotech. 2021 Jun;11(6):271
pubmed: 34017676
Int J Biol Macromol. 2017 Apr;97:209-217
pubmed: 28064053
ACS Appl Mater Interfaces. 2017 Jul 5;9(26):21809-21819
pubmed: 28589721
Int J Biol Macromol. 2014 Mar;64:334-40
pubmed: 24355618
Int J Nanomedicine. 2017 Mar 27;12:2361-2372
pubmed: 28392693
Eur J Pharm Biopharm. 2007 Feb;65(2):215-32
pubmed: 16982178
Biomater Sci. 2020 May 6;8(9):2590-2599
pubmed: 32238997
Eur J Pharm Biopharm. 2014 May;87(1):1-18
pubmed: 24530885
Materials (Basel). 2013 Nov 28;6(12):5549-5567
pubmed: 28788408
Nano Lett. 2016 Sep 14;16(9):5652-60
pubmed: 27541372
Pharmazie. 2016 Dec 1;71(12):691-700
pubmed: 29441997
ACS Pharmacol Transl Sci. 2022 Aug 05;5(9):774-790
pubmed: 36110378
Int J Nanomedicine. 2012;7:1761-79
pubmed: 22619526
Pharmaceutics. 2021 Jun 24;13(7):
pubmed: 34202604
ChemistryOpen. 2021 Mar;10(3):327-333
pubmed: 33590731
Colloids Surf B Biointerfaces. 2019 Jul 1;179:334-339
pubmed: 30986701
Nanoscale Res Lett. 2009 Jan 16;4(4):287-295
pubmed: 20596545
Front Pharmacol. 2018 Feb 09;8:1002
pubmed: 29479316
Int J Nanomedicine. 2015 May 04;10:3315-27
pubmed: 26005343
Adv Drug Deliv Rev. 2019 Jan 1;138:68-104
pubmed: 30553951
Biomolecules. 2020 Jan 02;10(1):
pubmed: 31906490
Nanoscale. 2015 May 7;7(17):7780-9
pubmed: 25848983
Int J Pharm. 2021 Sep 5;606:120867
pubmed: 34242629
Chem Rev. 2008 Jun;108(6):2064-110
pubmed: 18543879
Carbohydr Polym. 2022 Jul 15;288:119401
pubmed: 35450653
Nano Lett. 2016 Apr 13;16(4):2885-9
pubmed: 27007172
J Pharm Sci. 2022 Jun;111(6):1690-1699
pubmed: 34838781
Int J Biol Macromol. 2021 Dec 15;193(Pt A):53-63
pubmed: 34688674
Carbohydr Polym. 2016 Jan 20;136:1251-8
pubmed: 26572468
Chem Soc Rev. 2015 Dec 7;44(23):8576-607
pubmed: 26390044
Chem Soc Rev. 2021 Oct 18;50(20):11614-11667
pubmed: 34661212
PLoS One. 2022 Mar 18;17(3):e0265689
pubmed: 35303012
J Trop Med. 2016;2016:2853045
pubmed: 27956904
Nanomaterials (Basel). 2018 Nov 05;8(11):
pubmed: 30400634
Bioorg Med Chem Lett. 2005 Mar 1;15(5):1397-9
pubmed: 15713395
J Mater Sci Mater Med. 2009 Jan;20(1):301-7
pubmed: 18791664
Nanoscale. 2015 Jan 14;7(2):625-36
pubmed: 25423473
Antibiotics (Basel). 2018 Jun 09;7(2):
pubmed: 29890753
Sci Rep. 2020 Nov 3;10(1):18912
pubmed: 33144607
Int J Biol Macromol. 2017 Nov;104(Pt B):1853-1859
pubmed: 28359890
Biomed Pharmacother. 2017 Mar;87:223-229
pubmed: 28061405